De novo sequencing analysis
Report D161005PIJK_PI-Ref

SAMPLES
PI-reference: 1234
Date received: 01/10/2016
Number of samples: 1
Type of samples: Human cell line
Source of sample: Gel-band/Freeze-dried sample
Service required: De novo sequencing analysis

Samples were labeled as:

<table>
<thead>
<tr>
<th>Sample name</th>
<th>Molecular Mass (kDa)</th>
<th>PI-reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>X1</td>
<td>100</td>
<td>1234</td>
</tr>
</tbody>
</table>

METHODS
Protein samples were trypsin digested and peptides extracted according to standard techniques (Bringans et al. Proteomics 2008). Peptides were analysed by electrospray ionisation mass spectrometry using the Shimadzu Prominence nano HPLC system [Shimadzu] coupled to a 5600 TripleTOF mass spectrometer [AB Sciex]. Tryptic peptides were loaded onto an Agilent Zorbax 300SB-C18, 3.5 µm [Agilent Technologies] and separated with a linear gradient of water/acetonitrile/0.1% formic acid (v/v).

MS/MS spectra were analysed using PEAKS Studio Version 4.5 SP2 [Bioinformatics Solutions] and manual interpretation.

General comments for de novo sequencing:
* MS/MS interpretations represent a best fit of amino acids to the data; consequently sequences may not be exact.
* Ile/Leu are indistinguishable by MS and as such are interchangeable within a sequence.
* Lys (K) and Glu (Q) have near identical masses, hence an internal Q may represent an internal K cleavage site that has been missed.
* Arg/Lys can be present internally in a sequence if a trypsin enzyme cleavage site has been missed.

Accredited for compliance with ISO/IEC 17025, NATA accredited list of SOP's:
0_14 In-gel destain, reduction/alkylation, digestion & extraction of peptides
1_05 Operation of LC MS Instruments
1_09 De novo sequencing

SOPs carried out at Proteomics International Facility, located at Harry Perkins Institute of Medical Research, QEII Medical Centre, Nedlands, Perth, Australia.
RESULTS

The results provided relate only to the samples as listed above.

*De novo* sequencing results for 1 major peptide present in sample PI-Ref are shown in Tables 1 and 1a and the corresponding Figure 1.

In Table 1, the second and third columns show the sequential numbers and the m/z of the parent ions while the fourth column contains the deduced sequences. A maximum of 5 sequences (*i.e.* interpretations) are presented for any given ion. These are ranked based on their likelihood (0 to 4) with the ranking shown in the sixth column. The fifth column (titled Score) is also related to this ranking and shows the likelihood of any sequence amongst all possible interpretations for an ion.

Colors used to display the actual amino acids are indicative of the confidence in each amino acid assignment. The color-coded confidences are:
- **Red:** >90% confident
- **Purple:** 90-80% confident
- **Blue:** 80-60% confident
- **Black:** <60% confident

Amino acids assigned with confidence below 80% should only be used with caution. Fragment sequences for any given sample may be used individually or collectively to interrogate protein databases using a variety of algorithms. Nevertheless, the specialized algorithm for mass spectrometric analysis, MS BLAST, is often preferred over the general purpose programs such as NCBI BLAST. The algorithm may be found at:

MS BLAST* → http://genetics.bwh.harvard.edu/msblast/

*The original article by Shevchenko *et. al* (2001) that explains the application of MS BLAST may be found on this webpage.

All results and data will be available until 2018.

**Table 1: Sequencing results of sample PI-Ref**

<table>
<thead>
<tr>
<th>No.</th>
<th>m/z</th>
<th>Peptide</th>
<th>Score (%)</th>
<th>Rank</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>543.30</td>
<td>EPNKFVVPR</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EPNQFVVPR</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EPGGKFVVPR</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EPNGAFVVPR</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EPNAGFVVPR</td>
<td>0</td>
<td>4</td>
</tr>
</tbody>
</table>
Table 1a: Sequencing result for peptide m/z 543.30 (MH₂)²⁺ (PI-Ref).
Sequence: EPNKFVVPR

<table>
<thead>
<tr>
<th></th>
<th>b</th>
<th>sequence</th>
<th>y</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>E</td>
<td></td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>212.11</td>
<td>P</td>
<td>956.56</td>
<td>8</td>
</tr>
<tr>
<td>3</td>
<td>341.14</td>
<td>N</td>
<td>859.51</td>
<td>7</td>
</tr>
<tr>
<td>4</td>
<td>K</td>
<td></td>
<td>745.47</td>
<td>6</td>
</tr>
<tr>
<td>5</td>
<td>616.29</td>
<td>F</td>
<td>617.37</td>
<td>5</td>
</tr>
<tr>
<td>6</td>
<td>715.36</td>
<td>V</td>
<td>470.31</td>
<td>4</td>
</tr>
<tr>
<td>7</td>
<td>814.44</td>
<td>V</td>
<td>371.24</td>
<td>3</td>
</tr>
<tr>
<td>8</td>
<td>P</td>
<td></td>
<td>272.17</td>
<td>2</td>
</tr>
<tr>
<td>9</td>
<td>R</td>
<td></td>
<td>175.12</td>
<td>1</td>
</tr>
</tbody>
</table>

= detected y and b ions

Figure 1: *De novo* spectra for peptide m/z 543.30 (MH₂)²⁺ (PI-Ref).
Reference: 161003

With Compliments

Proteomics International

Authorised Signatory’s name
Andreja Livk
Contract Services Manager
This report should not be reproduced except in full written approval of Proteomics International.
All reports are supplied subject to Proteomics International's standard terms and conditions, available

Particular attention is drawn to clause 8:
LIABILITY & INDEMNITY
(a) Proteomics International (PI) shall not be subject to nor incur, and the Customer hereby releases PI from, any
claim, action or liability for consequential loss or damage to persons or property including, without limiting the
generality of the foregoing, loss of use of the Goods or services or loss of profits or loss on resale arising by reason
of delays, non-delivery, defective materials or workmanship, negligence or any act, matter, conduct or thing done,
permitted or omitted by PI.
(b) PI and the Customer hereby agree that, to the extent permitted by law, in the event of any loss, damage or claim
arising out of a breach of one or more of the warranties pursuant to these Terms and Conditions, the liability of PI (if
applicable) is limited to the replacement of the goods or the cost of replacement or, in the case of a service, the cost
of supply or re-supply of the service.
(c) The Customer’s property under PI’s custody or control will be entirely at the Purchaser’s risk as regards loss or
damage thereto or from whatsoever cause arising.
(d) The Customer shall comply with all instructions of PI in relation to the handling, storage, sale and the use of the
goods. Notwithstanding such compliance, the Customer shall keep PI indemnified against all costs, claims, demands,
expenses and liabilities of whatsoever nature, including without limitation, claims for death, personal injury, damage
to property and consequential loss (including loss of profit) which may be made against PI or which PI may sustain,
pay or incur as a result of or in connection with the manufacture, demand, expense or liability that shall be directly
and solely attributable to any breach of contract by, or negligence of, PI or a duly authorised employee of PI.
(e) All products and services are sold for research use only, and are not for human or drug use and should not be
relied upon for the purposes of clinical trial. PI is not liable and the customer agrees to indemnify PI for any loss or
expense for all claims or proceedings made or instituted against the customer of PI arising out of the application or
the use of the goods or services other than for in-vitro research purposes. The customer acknowledges that it does
not rely upon the skill and judgement of PI as to the suitability of its products or results provided for the purposes of
the customer.